What we do
Your Trusted Partner for Clinical-Grade Psychedelics
We develop and supply clinical-grade APIs of psilocybin, DMT, and 5-MeO-DMT, tailored for:
research
trials
applications
Our portfolio
Expanding
Horizons
We focus on high-potential compounds with proven therapeutic potential. We work closely with pharmas, clinics, and research institutions to ensure our compounds meet their unique needs.
Indicators
Optimizing Psychedelic Production to Increase Access
At EYWA Biotech, we are leading the next generation of mental health treatments by producing high-quality, accessible psychedelic compounds. We are on a mission to ensure a sustainable supply chain of psychedelic to combat mental health disorders on a global scale. Join Us!
Why Partner with EYWA?
Our cutting-edge and robust biosynthetic processes reduce environmental impact and production costs, offering a green alternative to traditional methods.
Our unique biosynthetic capabilities enable us to adopt a distinctive decentralized approach, addressing cross-border logistics challenges and ensuring timely access to essential therapies.
EYWA is at the forefront of developing novel full-spectrum formulations that maximize therapeutic benefits and expand treatment horizons.
Psychedelic API Solutions with EYWA
Our advanced biomanufacturing capabilities ensure the production of GMP high-purity psychedelic compounds, leveraging the power of synthetic biology to create cost-effective and environmentally friendly solutions. We are dedicated to pushing the boundaries of what’s possible in psychedelic medicine, offering tailored solutions that cater to the unique needs of researchers and pharmaceutical companies.
Our Unique Approach
Innovation Through Biosynthesis
While others replicate traditional methods, EYWA uses cutting-edge synthetic biology to create scalable and sustainable solutions ↘
Breaking the Mold in Mental Health
We believe that business as usual won't do for psychedelics. The world needs clinical- and pharmaceutical-grade psychedelic compounds designed with the utmost precision, safety, and scalability.
EYWA Biotech consist in a team of experts in biotechnology, synthetic biology, neuropharmacology, medicinal chemistry of psychedelic substances and business professionals, driven by the belief that psychedelic compounds hold significant clinical promise for treating neurological and psychiatric disorders, such as treatment-resistant depression, general anxiety and PTSD. We are convinced that the best way to advance scientific research on the therapeutic use of psychedelics is to ensure researchers have reliable and easy access to high-purity Active Pharmaceutical Ingredients (API).
EYWA stands by the principle that the potential of psychedelic compounds can be enhanced. We also focus on developing next-generation molecules with the idea of enabling diverse solutions for application in diverse therapeutic contexts.
Indicators
After decades of stagnation in the search for new treatments, we are excited to explore the prospect of affordable and scalable methods of the Active Principal Ingredients (APIs) in psychedelic substances. At EYWA we are pioneering the biocatalytic process of production of API compounds in psychedelic substances. After a year of therapy:
Why Invest in EYWA Biotech?
The Growing Psychedelics Market
The global psychedelics market is projected to grow at a 16% CAGR and reach $6.9B by 2027. As the first Latin American company specializing in clinical-grade APIs for psychedelics, Eywa is uniquely positioned to lead this transformation.
Leading the way in new therapies: EYWA’s team
Our team combines expertise in chemistry, biotechnology, and business development to advance psychedelic therapies
.png)
Press release
Thanks for trusting us
Invest in the Future of Psychedelic Therapeutics
